The median number of baseline plasma ctDNA KRAS copies was higher in patients with stage IV versus stage III PDA (608.2 versus 56.0 copies per 105 GEq; p < 0.0001) (Figure 2A). The gene discussed is KRAS; the disease is Patent ductus arteriosus.